Altimmune, Inc. ALT
2.04 USD +0.02 (+0.99%)
At closeNov 3, 2026, 4:51 PM EST
2.08 +0.04 +1.96%
After hours · Nov 3, 4:51 PM ET
2.03 Day range 2.08
1.99 52-week range 6.44
- YTD
- -43.49%
- 1 year
- -48.48%
Analyst view
Consensus: buy
Buy
Price target (mean) 22.86 +1020.4% upside
Now 2.04
- Target (low)
- 12.00
- Target (mean)
- 22.86
- Target (high)
- 28.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 9
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.24 | -0.39 – 3.02 | -0.3289 | +173.0% | 0 | -100.0% | 6 |
| Next quarter | -0.33667 | -0.35 – -0.32 | -0.34 | +1.0% | 1.00K | -80.0% | 5 |
| Current year | -0.80333 | -1.40 – 1.96 | -1.43 | +43.7% | 3.57K | -99.2% | 6 |
| Next year | -1.09 | -1.97 – 0.73 | -0.80333 | -36.1% | 28.57M | +800300.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 12, 2024 | UBS | Initiated | — | Buy |
| Aug 12, 2024 | B. Riley Securities | Reiterated | Buy | Buy |
| Jun 25, 2024 | B. Riley Securities | Reiterated | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 10, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Apr 29, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 1, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 28, 2024 | B. Riley Securities | Reiterated | Buy | Buy |
| Feb 13, 2024 | B. Riley Securities | Maintained | Buy | Buy |
| Dec 1, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 9, 2023 | B. Riley Securities | Maintained | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 11, 2023 | B. Riley Securities | Maintained | Buy | Buy |
| Jul 12, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 31, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Mar 22, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Mar 22, 2023 | Goldman Sachs | Downgrade | Buy | Neutral |
| Mar 9, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 6, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Jan 20, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 18, 2023 | Evercore ISI Group | Maintained | — | Outperform |
| Dec 1, 2022 | Goldman Sachs | Initiated | — | Buy |
| Nov 11, 2022 | JMP Securities | Maintained | — | Market Outperform |
| Sep 16, 2022 | Guggenheim | Maintained | — | Buy |
| Aug 31, 2022 | Jefferies | Maintained | — | Buy |
| Aug 17, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 12, 2022 | B. Riley Securities | Maintained | — | Buy |